Thymodepressin: D-amino-acid dipeptide claim — US5736519A
Vladislav I. Deigin, Andrei Marxovich Korotkov · 1998 · US5736519A · patent family 20168146
Published 1998-04-07.
Reported patent results
Reported findings
The patent reports context-dependent marrow recovery and improved survival in preclinical models.
Thymodepressin-related D-amino-acid peptide mouse studies, including cytostatic-associated cytopenia and allogeneic marrow-transplant observations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cytopenia experiment | Marrow karyocytes >2-fold, CFU-S-8 nearly 3-fold and CFU-S-12 >2-fold higher than cytostatic-only controls | 24 mice total; 12 received the peptide · Day 7 marrow examination |
| Transplant-associated survival | 45-day survival described as almost doubled versus control | Absolute survivor counts and schedule-specific denominators not transcribed · 45 days |
Marrow recovery after injury does not mean general immune stimulation or prove autoimmune treatment benefit. These are animal observations with incomplete quantitative extraction.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. Claim 3 identifies the D-glutamyl/D-tryptophan dipeptide associated with Thymodepressin within an immunosuppressive peptide program.
Linkage and stereochemistry distinguish this compound from Thymogen and Bestim; a patent does not demonstrate autoimmune efficacy.
- Publication
- US5736519A ↗ · 1998-04-07
- Earliest priority / filing
- 1995-06-07 / 1996-06-07
- Original applicant / assignee
- Individual
- Indexed status
- Expired - Lifetime · checked 2026-11-06
- Patent family
- 20168146 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
Inventors: Vladislav I. Deigin; Andrei Marxovich Korotkov.
US5736519A · EP0832900B1 · JP4082522B2 · CN1154653C · ATE260933T1 · AU724781B2 · BRPI9609235B8 · CA2222296C · CZ287816B6 · DE69631762T2 · DK0832900T3 · ES2217311T3 · HU228461B1 · LT4476B · LV12074B · PT832900E · RU2107692C1 · SK281825B6 · UA48974C2 · WO1996040740A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Linkage and stereochemistry distinguish this compound from Thymogen and Bestim; a patent does not demonstrate autoimmune efficacy.
- Marrow recovery after injury does not mean general immune stimulation or prove autoimmune treatment benefit. These are animal observations with incomplete quantitative extraction.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20168146. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Vladislav I. Deigin, Andrei Marxovich Korotkov. Thymodepressin: D-amino-acid dipeptide claim — US5736519A US5736519A · patent family 20168146 1998.
Molekul research summary: https://molekul.io/research/patent-us5736519a. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry